QLM Technology is developing advanced quantum lidar camera technology to identify greenhouse gas emissions. With continuous monitoring, cost-effective and 3D accuracy capabilities, it offers an effective and scalable solution to pinpointing leaks of the world’s largest emitters, like methane, within the oil and gas industry.

Herd Climate is a not-for-profit addressing the pressing agricultural challenge of enteric methane emissions produced by farming animals. It works directly with farmers, researchers and young people to bridge the gap between climate-smart scientific advancements and on-the-ground practices through innovative research, accessible science communication and engaging networking events. This equips agricultural communities - who are at the forefront of climate solutions - with actionable insights for collaborative, sustainable farming practices.

Lifecare is committed to improving the lives of people and pets with diabetes. It is developing the next-generation of miniaturized and implantable nanobiosensors for correct and continuous monitoring of glucose and other biomarkers to the market. The company’s spin-off entity Lifecare Chemistry Ltd was founded to enhance research collaboration and secure ownership of its improved analyte-specific chemical receptor developments.

neo-fossil is developing new technology using cell engineering to help reverse the threat of climate change. By optimising biology, it is creating new fossils that harvest atmospheric carbon dioxide, storing it for centuries.

Hone Bio is revolutionising drug delivery using lipid nanoparticles (LNPs) and exploring their potential across multiple therapeutics, including cell and gene therapies, vaccines and autoimmune diseases. Its NanoPilot platform technology engineers LNPs to target specific cell types with extreme precision to optimise drug effectiveness by minimising off-target effects that tend to accumulate in the liver. This unlocks new possibilities for using LNPs to safely treat diseases in other parts of the body that require maximum target specificity in their drug delivery.

CellVoyant is accelerating the development of novel stem cell-based therapies for chronic diseases. Its technology uses AI-first live cell imaging to predict and optimise stem cell differentiation, enable advanced cell analytics and ultimately unlock the controllable manufacturing of any cell and tissue in the body at scale. Built on foundational research at the University of Bristol, CellVoyant works at the intersection of cell biology, computing, engineering and machine learning to carry out its mission.